Peer mentor aids end-of-life planning: study
Posted on: Tuesday, 12 July 2005, 16:07 CDT
NEW YORK (Reuters Health) - Peer mentoring, in which trained patients educate other patients, offers a culturally sensitive way to inform dialysis patients about their condition and treatment options, new research suggests.
Within cultural groups with oral rather than written traditions, this person-to-person approach appears to encourage discussion about living wills (advance directives) and end-of-life decision-making.
Because of the high death rate among dialysis patients, death and end-of-life discussions are critically important for the dialysis community, Erica Perry, from the National Kidney Foundation of Michigan in Ann Arbor, and colleagues note in the American Journal of Kidney Diseases this month.
They explored the impact of peer mentoring compared with standard printed materials on end-of-life decision-making in 203 dialysis patients.
The mentors attended a workshop on advance directives, and received training through role-playing and direct instruction on communicating about end-of-life planning.
During the study, patients assigned to peer intervention were contacted eight times by mentors to talk about coping with chronic illness, the impact on family, and eventually the value of completing a living will.
Compared with standard printed materials, the use of peer mentoring significantly increased the odds that advance directives would be completed (12 percent vs. 35 percent), the authors report.
The benefits were most pronounced in African American subjects for whom significant improvements in comfort discussing such directives, subjective well-being, and anxiety levels were also seen. By contrast, these effects were not seen among white subjects. However, printed materials seemed to reduce suicidal thoughts among whites.
"Peer mentoring in dialysis units appears to address differences in cultural value systems, allay anxiety, and promote discussion and acceptance of advance directive planning and, to some degree, death itself," the authors conclude.
SOURCE: American Journal of Kidney Disease, July 2005.
Source: REUTERS
Related Articles
- Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection
- Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
- Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
- Advanced Life Sciences Announces Second Quarter 2008 Financial Results
- Advanced Life Sciences' Pneumonia Drug Meets Trial End Point
- Advanced Life Sciences Announces Formation of National Advisory Board for Cethromycin
- Advanced Life Sciences Announces First Quarter 2006 Results
- Advanced Life Sciences to Host 2005 Fourth Quarter and Year End Financial Results Conference Call and Live Webcast
- Advanced Life Sciences Awarded Phase I Small Business Innovation Research Grant to Study Drug Against Stroke in Preclinical Tests
- FDA Provides Guidance on Advanced Life Sciences' Pivotal Phase 3 Clinical Protocol Evaluating Cethromycin in Community Acquired Pneumonia
User Comments (0)

RSS Feeds